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Abstract 
Understanding tumor genomic heterogeneity may offer vital information in an age of targeted 
therapy for renal cell carcinoma. We sought to investigate hallmark truncal chromosomal 
alterations between conventional, sarcomatoid, and matched metastatic tumor foci in clear cell 
and papillary renal cell carcinomas.  A retrospective review identified 58 cases including clear 
cell (CCRCC) and papillary renal cell carcinomas (PRCC). All cases contained sarcomatoid 
transformation. Additionally, 10 of 58 patients had matched metastatic disease available for 
analysis. Three separate foci of conventional and sarcomatoid morphologies were analyzed in 
each tumor using dual color interphase fluorescence in situ hybridization. In the CCRCC cohort, 
hallmark chromosome 3p deletion was identified in 71% of cases (37/52). Complete 
concordance of chromosomal status between intratumoral foci in sarcomatoid and conventional 
foci was 89% and 86%, respectively. Overall chromosome 3p status between matched 
conventional and sarcomatoid morphologies was identified in 98% of cases (51/52). Hallmark 3p 
deletion was present in 91% of CCRCC metastatic samples (10/11) and was concordant with the 
matched primary CCRCC tumor in 91% (10/11). In the PRCC cohort, trisomy 7 and 17 was 
identified in all six cases (6/6).  Complete concordance between intratumoral foci of trisomy 7 
and 17 was 83% (5/6). Trisomy 7 and 17 were identified in all metastatic PRCC samples with 
100% concordance with the matched primary tumor. These data show the relative preservation of 
truncal chromosomal abnormalities between conventional and sarcomatoid morphologic as well 
as matched metastatic settings. This article is protected by copyright. All rights reserved 
Keywords: Kidney; sarcomatoid renal cell carcinoma; fluorescence in situ hybridization (FISH); 
molecular genetics/cytogenetics; targeted therapy; precision medicine; differential diagnosis 
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Introduction 
The morphological and genetic complexities of renal cell carcinoma (RCC) have been 
extensively studied. Additionally, several recent studies have used genomic sequencing to 
highlight intratumoral genetic heterogeneity.[1-6] Such complexities are compounded by the 
predisposition of a subset of RCC to undergo sarcomatoid differentiation. RCC with sarcomatoid 
features, regardless of the conventional morphologic subtype, has been shown to be associated 
with an overall worse prognosis.[7] Accordingly, studies have attempted to characterize the 
extent of intratumoral heterogeneity within sarcomatous tumor components and compare the 
differences between conventional (e.g. epithelial) and sarcomatous elements.[8,9] 
Intratumoral genetic heterogeneity, particularly in the setting of divergent morphologic 
features and/or high clinical stage, may have significant impact on treatment options for patients, 
especially those with metastatic disease[10]. Hallmark chromosomal gains and losses in primary 
RCC have been characterized, most notably the presence of chromosome 3p deletion in clear cell 
RCC (CCRCC) and trisomy 7 and 17 in papillary RCC (PRCC)[11-20]. Prior studies have 
attempted to compare intratumoral concordance of hallmark chromosomal gains and losses and 
subsequent concordance with matched metastases.[21-23] We herein investigate the preservation 
of hallmark chromosomal abnormalities along with intratumoral concordance in the setting of 
matched sarcomatous transformation and matched metastatic disease in CCRCC and PRCC. 
Materials and Methods 
Fifty-eight patients diagnosed with either CCRCC (52 patients) or PRCC (6 patients) 
with sarcomatoid transformation between 1995 and 2016 were retrieved from our institution’s 
surgical pathology files. Histopathologic features of each case were evaluated by a single senior 
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genitourinary pathologist (LC) and confirmed using diagnostic criteria set forth in the World 
Health Organization Classification of Tumors of the Urinary System and Male Genital 
Organs.[24] Appropriate sections containing both conventional and sarcomatoid tumor foci were 
selected for subsequent analysis. Specimens of biopsy/resection-proven metastatic tumors of the 
patients were also identified and lesions were matched with primary lesions for analysis. This 
study was approved by the Institutional Review Board. 
Formalin-fixed, paraffin-embedded tissue blocks of each tumor were obtained based on 
correlation with the reviewed hematoxylin and eosin–stained glass slides demonstrating 
conventional (epithelial) and sarcomatoid morphologies. Three separate foci of conventional and 
sarcomatoid morphologies were analyzed in each primary tumor. When available, three foci of 
metastatic RCC were marked, analyzed, and compared to their primary RCC (Figure 1). 
Fluorescence in situ hybridization (FISH) analysis was performed on each of these selected foci 
to identify the presence of hallmark chromosomal abnormalities associated with CCRCC and 
PRCC including deletion of 3p and trisomy 7 and 17, respectively, as described 
previously.[25,26] 
Selected slides were deparaffinized with two washes of xylene, 15 min each; washed 
twice with absolute ethanol, 10 min each; and air-dried in a fume hood. Subsequently, the slides 
were treated with 0.1mM citric acid (pH 6.0) at 95 degrees for 10 min, rinsed in distilled water 
for 3 min, and followed by a wash of standard saline citrate (2 × SSC) for 5 min. Tissue 
digestion was performed by applying 0.4 ml of pepsin (Sigma, St. Louis, MO, USA) solution (4 
mg/ml in 0.9% NaCL in 0.01N HCl) to each slide and incubating the slides in humidified box for 
40 min at 37 °C. The slides were rinsed with distilled water for 5 min, washed with SSC for 5 
min, and air-dried. 
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The alterations in chromosomes 7 and 17 were assessed using a probe cocktail containing 
probe CEP7 (green) and CEP17 (orange). The CEP7/CEP17 probe set was diluted with 
tDenHyb1 (Insitus, Albuquerque, NM, USA) in ratios of 1:50 and 1:100, respectively. Deletion 
of chromosome 3p was assessed using a probe cocktail containing BAC clone probe to 
chromosome 3p25 (RP11-572 M14, Green; Empire Genomics, Buffalo, NY, USA) and CEP3 
(CEP3-Orange; Abbott, Downers Grove, IL, USA). The VHL gene was mapped at 3p25.3 
(chr3:10,141,008-10,153,670). The BAC clone RP11-572M14 (chr3: 10,011,785-10,180,797) 
covers 100% of the gene VHL. The 3p25/CEP3 probe set was diluted with tDenHyb2 (Insitus) in 
ratios of 1:50. The diluted probe (5 μl) was applied to each slide under reduced light conditions. 
The slides were then covered with a 22 × 22 mm coverslip and sealed with rubber cement. 
Denaturation was achieved by incubating the slides at 83 °C for 10 min in a humidified box and 
hybridization at 37 °C overnight. The coverslips were removed, and the slides were washed 
twice with 0.1 × SSC/1.5 M urea at 45 °C (20 min for each), followed by a wash with 2 × SSC 
for 20 min, and with 2 × SSC/0.1% NP-40 for 10 min at 45 ºC. The slides were further washed 
with 2 × SSC at room temperature for 5 min. The slides were air dried and counterstained with 
10 μl 4,6-diamidino-2-phenylindole (Insitus), covered with coverslips, and sealed with nail 
polish. 
The hybridized slides were observed and documented using a MetaSystem FISH system 
(MetaSystem, Newton, MA, USA) under ×100 oil objective. The images were acquired with a 
cool box camera and analyzed with MetaSystem Isis software (MetaSystem). The following 
filters were used: SP-100 for DAPI, FITC MF-101 for spectrum green, and Gold 31003 for 
spectrum gold signals. Signals from each color channel (probe) were counted under false color, 
with computerized translation of each color channel into blue, green, and red. Four sequential 
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focus stacks with 0.3-μm intervals were acquired and integrated into a single image to reduce 
thickness-related artifacts. 
Analysis was performed identifying 100–150 nuclei from tumor tissue for each slide and 
was scored for probe signals under the fluorescence microscope with ×1000 
magnification[16,27]. Definitions of chromosomal trisomy for chromosomes 7 and 17 were 
based on the Gaussian model and were related to the nonneoplastic renal cortex control cell 
signals. The cutoff values were set for each probe at the mean plus 3 standard deviations of the 
control values. The method of analysis for 3p25 deletion was based on previous studies of 
chromosome deletions at 1p and 19q in oligodendrogliomas. The cutoff value for 3p deletion 
was defined as a 3p25/CEP3 ratio of ≤0.7. Chromosome 3p deletion was considered to be 
characteristic of CCRCC and trisomy of chromosomes 7 and/or 17 was considered characteristic 
of PRCC. 
 
Results 
We identified 58 patients with CCRCC (n=52) or PRCC (n=6) tumors with sarcomatoid 
features, additionally 13 samples (CCRCC n = 11; PRCC n = 2) of metastatic disease from 10 
different patients were available for comparative analysis to the primary tumor. All tumors were 
the International Society of Urological Pathology (ISUP; formerly Fuhrman) nuclear/nucleolar 
grade 4 of 4. The male-to-female ratio was 1.5:1 and the mean age was 57 years at the time of 
the primary resection (median, 57; range, 28–77 years). The degree of sarcomatoid features in 
the primary tumor ranged from <5–90%. Primary renal tumor sizes ranged from 2.0–20.5 cm and 
metastatic sites included lymph nodes, bone, gastrointestinal tract, lung, brain, and liver. A 
chromosomal aberration in at least one tumor focus was considered adequate to classify a 
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morphologic component as deletion (e.g., chromosome 3p) or polysomy (e.g., chromosome 
7/17). 
 
Clear Cell Renal Cell Carcinoma 
The study cohort of CCRCC with sarcomatoid features included 52 patients with a male-
to-female ratio of 1.3:1 and mean and median ages of 57 and 59 years, respectively. The primary 
tumor sizes ranged from 4.3–20.5 cm (mean, 10.6 cm). Pathologic stages of primary tumors 
(when available) were T1b (n=3), T2a (n=1), T2b (n=2), T3a (n=30), T3b (n=2), and T4 (n=4). 
The percentage of sarcomatoid features in the primary CCRCC tumors ranged from <5–90%. 
Eleven metastatic tumor site samples from 8 different patients were available for comparison to 
their primary CCRCC including bone (n=3), brain (n=2), gastrointestinal (n=2), liver (n=2), 
lymph node (n=1), and lung (n=1) [Table 1]. 
Of the 52 CCRCC with sarcomatoid features, chromosome 3p deletion was identified in 
71% of cases (37/52) (Figure 2). When chromosomal alterations between the 3 selected 
sarcomatoid tumor foci were compared, complete concordance of chromosome 3p deletion in all 
3 foci was identified in 32 of 37 cases (86%). Three of the remaining cases with chromosome 3p 
deletion demonstrated absence of deletion at a single focus within the sarcomatoid component 
and 2 cases showed absence at 2 of 3 foci. In comparison, the 3 selected conventional CCRCC 
tumor foci showed complete concordance of hallmark chromosome 3p deletion in 31 of 36 cases 
(86%). Three of the remaining cases with chromosome 3p deletion demonstrated absence of a 
deletion in a single tumor focus with the final 2 cases showing absence of 3p deletions at 2 of 3 
foci. Complete concordance between conventional clear cell and sarcomatoid morphologies of 
lesions was identified in 81% of cases (42/52); however, concordance of overall chromosome 3p 
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status (including concordant and discordant 3p deletions) between the morphologic components 
was 98% (51/52) (Figure 3). Only one case demonstrated absence of chromosome 3p deletion in 
all 3 foci of conventional CCRCC while demonstrating 3p deletion in all 3 sarcomatoid foci. 
Hallmark 3p deletion was present in 91% of CCRCC metastatic samples (10/11). Metastases 
showed 91% (10/11) concordance between matched primary conventional and sarcomatoid 
tumor foci (Figure 4). Of note, one case demonstrated an absence of 3p deletion in all 3 
metastatic foci compared to the primary tumor. Importantly, all 11 metastatic lesions showed 
complete concordance between all 3 tumor foci. 
 
Papillary Renal Cell Carcinoma 
The study cohort of PRCC with sarcomatoid features included 6 patients with a male-to-
female ratio of 5:1 and mean and median ages of 54 and 56 years, respectively. The primary 
tumor sizes ranged from 2.0–15 cm (mean, 7.1 cm) and pathologic stages of primary tumors 
were T1a (n=1), T2a (n=2), and T3a (n=3). The percentage of sarcomatoid features in the 
primary PRCC tumors ranged from <5–60%. Corresponding specimens of metastatic disease 
were identified in 2 patients and the sites included small bowel (n=1) and lung (n=1) [Table 1]. 
Trisomy 7 and 17 were identified in 100% (6/6) of PRCC tumors with sarcomatoid 
features. When comparing chromosomal alterations between the 3 selected sarcomatoid tumor 
foci, complete concordance was identified in 83% (5/6) of cases (Figure 5). A single focus in 
one case demonstrated disomy 7 and 17 within the sarcomatoid component. In comparison, 
findings among the 3 selected conventional PRCC tumor foci showed complete concordance in 
83% (5/6) of cases. Again, a single focus in one case demonstrated disomy 7 and 17. The overall 
concordance of matched sarcomatoid and conventional features in the PRCC cohort was 100% 
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(6/6). Trisomy 7 and 17 was present in all PRCC metastases (2/2) and showed 100% 
concordance with primary conventional and sarcomatoid tumor foci (Figure 6).  
 
Discussion 
In this study, we evaluated the presence and maintenance of truncal chromosomal 
aberrations of multiple tumor foci in matched conventional and sarcomatous components of 
primary RCC. CCRCC is the most common RCC subtype and mutations of von Hippel Lindau 
gene (VHL) and the loss of chromosome 3p are fundamental events in development.[13,14,28] 
Previously, discordant 3p deletion patterns have been shown in multifocal CCRCC (intrarenal 
metastatic spread)[26]; however, Gerlinger et al have demonstrated preservation of chromosome 
3p deletion sampling multiple regions of 10 CCRCC cases.[4] Our study includes 58 different 
patients and considering the multifocal sampling performed, we were able to evaluate the 
chromosomal status of 374 primary tumor foci. With 13 samples of metastatic tumor from 10 of 
58 patients, our total foci for comparison became 387. While recent studies have highlighted 
variations in the subclonal population identified by genomic sequencing, our multifocal intra- 
and intertumoral evaluation of hallmark chromosomal aberrations serves to highlight impressive 
concurrence of chromosomal status in the setting of divergent morphology and metastasis.[29]  
Sarcomatoid divergence in RCC is associated with aggressive behavior, high 
pathologic/clinical stage, and overall poor prognosis.[7] Approximately 5–10% of RCC have 
some component of sarcomatoid morphology.[7] The underlying mechanisms of transition to 
sarcomatoid differentiation have been extensively hypothesized; however, regardless of such 
purported mechanisms causing this divergence, limited prior study shows chromosomal 
aberrations of the conventional components appear to be maintained.[30] Prior landmark 
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genomic studies in RCC subtypes typically excluded cases with divergent morphology, which 
explains the paucity of data evaluating preservation of these recurrent chromosomal aberrations 
in the setting of sarcomatoid differentiation [9].  
Cancer evolution remains an extensively studied concept and encompasses a complicated 
series of molecular events. While hypotheses and opinions differ, it appears that RCCs arise from 
a single clonal event which subsequently branch (or “braid”) into subclonal events. A key point 
of contention is how these subclones interact, if at all, as the tumor evolves [17,20,31]. Herein 
lays the debate between linear versus braided evolution from a truncal event in 
tumorigenesis.[32] Furthermore, the “braided” model hypothesizes that spatially heterogenous 
mutations may happen at different points in time but the overall genomic profile inevitably 
becomes similar [33]. Given that many subclones are point mutations or short segment gains and 
losses, FISH study methodology is crucial. Analytical resolution of FISH is determined by probe 
size and labeling methods[16]. By using plasmid or oligo probes, detection could increase 
resolution to 2-3 KB level. These types of probes are especially useful for the detection of micro-
deletions but with reduced sensitivity. It is still unclear how these small genetic lesions interact 
with clinical tumor progression or contribute to possible resistance to treatment.[21] Regardless, 
many of these subclones, while being genetically distinct, do share identical driver mutations 
[29,34,35].  
Regardless of the role of subclones in tumor evolution, chromosome 3p abnormalities in 
CCRCC and trisomy 7/17 in PRCC remain significant in tumorigenesis and targeted treatment 
[8,25]. In CCRCC, these abnormalities directly relate to the VHL gene, which is located at 3p25. 
Variations in VHL expression have direct consequences to three key pathways including the 
hypoxia-inducible factor (HIF), mammalian target of rapamycin (MTOR), and overexpression of 
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vascular endothelial growth factor/platelet-derived growth factor (VEGF) [14,17,22,32]. VHL is 
a ligase responsible for degrading HIF1/2A. Given the vascular nature of CCRCC, the 
angiogenesis seen in these lesions is likely a direct result of this uninhibited activation.[36] The 
importance of chromosome 3p deletion and VHL genetic alterations stems from their function as 
truncal drivers in the development of CCRCC [4,16,17,19]. Mutations in PBRM1, SETD2, and 
BAP1 have been identified in CCRCC and are notably located on the short arm of chromosome 
3p (all within a 50-Mb region), highlighting further importance in assessing 3p 
mutations/deletions [14,37]. 
Similar to the hallmark chromosome 3p deletion in CCRCC, the study by Kovac et al 
describes similar evolution of PRCC from a truncal chromosomal alteration, such as trisomy 
chromosome 7 and/or 17, followed by subsequent subclonal mutations.[12] While types 1 and 2 
PRCC have been shown to be genetically and clinically distinct, a substantial majority show 
chromosomal gains of 7 and 17.[38] PRCC mutations also include MET, NF2 (in the Hippo 
signaling pathway), and PNKD which occur on chromosome 7 [39]. Drugs such as foretinib 
which is a mutikinase agent targeting MET, AXL, and other receptors have been used [40]. 
Some evidence has been shown to suggest chemotherapeutic agents used to treat CCRCC, 
including sunitinib, sorafenib, and mTOR inhibitors such as everolimus and temsirolimus, also 
show efficacy in other RCC subtypes including PRCC and chromophobe renal cell 
carcinoma[41]. Interestingly, Foretinib appears to benefit patients with germline MET mutations 
compared to all PRCC patients [40]. 
In current models of RCC evolution and of cancer progression, prior data suggest that 
conventional and sarcomatoid tumor components likely arise from a common progenitor cell 
with subsequent subclonal populations arising as the tumor progresses.[8,9] It has been reported 
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that areas of sarcomatoid differentiation in RCC have increased mutations and greater loss of 
heterozygosity.[42] Gulati et al among other previous studies evaluating intratumoral 
heterogeneity, particularly at the subclonal level, have argued that single focus sampling is 
insufficient for true molecular classification of individual tumors.[10,43,44] Previously, Kouba 
et al have compared mutational variability between primary and matched metastatic lesions, 
which have shown similarities in a majority of tumor pairs.[21,45] Conversely, a study by Huang 
et al demonstrated chromosome 3p deletions in metastatic RCC that were not present in the 
primary tumor, which was identified in a single case within our current study.[5] Ito et al have 
demonstrated foci of sarcomatoid morphology or matched metastatic sites may contain high rates 
of chromosomal imbalances, but we have demonstrated that truncal hallmark drivers are often 
maintained.[6] Other histologic types of RCC, such as chromophobe RCC, have been shown to 
contain similar preservation of genetic abnormalities between primary and matched metastatic 
lesions.[46-48] Several studies have argued that metastatic lesions are less heterogeneous, but 
also completely different genetically, from their primary lesion.[5] Our study highlighted 
complete chromosomal concordance between all tumor foci within each metastatic lesion in both 
CCRCC and PRCC.  
Overall, the 5-year survival for RCC ranges from 61–72%.[49,50] Regardless of the 
histologic subtype, high-stage RCC disease has a 5-year survival rate of 53% and only 8% with 
metastatic disease.[51] Adjuvant chemotherapy has historically been reserved for RCC patients 
with metastatic disease.[52,53] Ravaud et al have suggested that adjuvant treatment with high-
risk nonmetastatic RCC could provide significantly longer disease-free survival.[54] VHL 
mutations are associated with dysregulated angiogenesis. Tyrosine kinase inhibitors, including 
sunitinib, sorafenib, pazopanib, axitinib, levatinib, and cabozantinib and remain first line therapy 
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in metastatic RCC, have been used in treatment of advanced RCCs since the early 21st 
century.[11,55-57] Success using these chemotherapeutic agents appears to stem from targeting 
activating mutations of angiogenesis by way of VEGF receptors and the MTOR[33,58,59]. Some 
evidence has been shown to suggest chemotherapeutic agents used to treat CCRCC, including 
sunitinib, sorafenib, and mTOR inhibitors such as everolimus and temsirolimus, could also show 
efficacy in other RCC subtypes including PRCC and chromophobe renal cell 
carcinoma[14,41,60]. The VHL gene, located on chromosome 3p25, has been shown to be a 
tumor suppressor gene; therefore, deletion or inactivation has been attributed to downstream 
effects on HIF.[14,61] Demonstration of preserved chromosome 3p deletions in intratumoral and 
metastatic foci is of importance given the first line targeted therapies in chemotherapeutic 
regimens. In addition to its correlation with VHL, chromosome 3p deletion has been attributed 
with better overall survival in CCRCC patients. Of note, correlating overall survival as it relates 
to chromosome 14q (which harbors the HIF1A gene) status has also been evaluated.[62]  
As previously stated, studies have postulated that intratumoral heterogeneity contributes 
to therapeutic resistance likely secondary to intratumoral genetic heterogeneity by a combination 
of genomic instability and Darwinian cancer evolution.[2,10,29] Furthermore, these studies 
maintain that genomic/genetic reprofiling of metastatic lesions could be a novel approach to 
identify causes of resistance to anti-VEGF inhibitors.[23] Genetic overlap between CCRCC and 
PRCC, upwards of 100 genes, has been described.[63] Of note, resistance to first line VEGF 
inhibitors has been attributed to mutations in tyrosine kinase pathways (e.g. MET or AXL). 
Combination therapy or use of drugs that target both VEFG and MET pathways (e.g. 
cabozantinib) could in theory address this issue, but toxicity with agents remains a serious issue 
in RCC treatment[53].While both tumors have similar treatment modalities in the metastatic 
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setting, a study by Voss et al postulated that the decreased effectiveness of treatment of 
metastatic PRCC is likely secondary more to the use of antiangiogenic therapies in a tumor that 
typically lacks VHL loss rather than resistance secondary to tumor heterogeneity.[64] 
Unfortunately, challenges in treating metastatic PRCC appear to go beyond targeting a truncal 
clonal chromosomal alteration (e.g., trisomy 7 or 17). While combination chemotherapeutic 
drugs like foretinib, a MET/VEGF inhibitor, may show efficacy in patients with PRCC (as the 
MET gene is located on chromosome 7), the complex genetic landscape of these tumors 
continually poses a challenge to treatment.[40,53,65]  
Our current study has corroborated many prior molecular findings in CCRCC and PRCC, 
such as hallmark abnormalities and relative preservation of chromosomal status by multifocal 
analysis. Unfortunately, this has not elucidated why efficacy of chemotherapeutic agents is so 
poor. Given that mutations/alterations in CCRCC, including lesser known mutations such as 
BAP1 and SETD2, typically occur on the short arm of 3p, current regiments targeting these 
regions have done little to improve overall survival and disease-free survival[14]. While we may 
have been able to prove that CCRCC and PRCC tumors retain similar chromosomal status 
regardless of tumor divergence or metastasis, this unfortunately also highlights that tumor 
progression likely goes beyond the pathways described above.  
One potential limitation identified in this study is the ability to identify all possible 
chromosome 3p genetic alterations in clear cell renal cell carcinoma by FISH studies[16-19]. In 
the current study, the BAC clone probe used was 169K in size. According to other metaphase 
and molecular studies, the majority of the 3p deletions in CCRCC were in the pattern of 3p13-
ptar or 3p25-pter deletion, and microdeletions were not typically reported in CCRCC 
[4,13,14,66,67]. Since the previously reported deletions were far greater in size than that of the 
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probe (169KB), we felt a vast majority would be detectable by the probe. The histograms 
(Figure 3G and 6E) represent the signal pattern distribution from 100 typical tumor cells from 
CCRCC (3G) and PRCC (6E). The x-axis represents the signal patterns and the y-axis represents 
the cell numbers that baring a specific signal pattern. The 3p25 deletion histogram demonstrated 
that more than 60% of the tumor cells presented as 1G2R pattern (3p25 deletion). A small 
population of cells also showed disomic (2G2R), section truncations (1G/1R or 2G1R) or more 
than 3 of G/R signals, which may represent the DNA replication in the population of mitotic 
cells. For the chromosome 7/17 enumeration, the histogram showed that about 80% of cells 
demonstrated trisomy (all populations with 3G signal pattern, while the chromosome 17 trisomy 
frequency was about 70% of total tumor cell populations. The histogram shows that the current 
threshold could effectively detect the chromosome deletion and gains. 
While a majority of allelic loss occurs by simple deletion, a subset of tumors have been 
shown to incur loss of chromosome region by uniparental disomy (UPD) or copy-neutral loss of 
heterozygosity (LOH)[68]. Traditionally UPD, which occurs when a person inherits two 
chromosomal copies from the same parent and none from the other, had been associated with 
inherited-type diseases [18,69]. However, prior studies have shown this can occur in an acquired 
fashion in hematopoietic and solid organ malignancies [70-72]. Unfortunately, these LOH or 
copy number-neutral changes could not be detectable by current FISH platforms, despite using a 
BAC clone probe (RP11-572M14, chr3: 10,011,785-10,180,797) that covers the entire sequence 
of VHL gene (VHL, chr3:10,141,008-10,153,670) [16,17,25,26,69,73]. Further molecular 
analysis, particularly by high-resolution single-nucleotide polymorphism microarrays, may serve 
to identify an even higher percentage of alterations in 3p chromosomal regions in future studies 
[8,16,17,26,68].  
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RCC with sarcomatoid features is an aggressive, heterogeneous subset of tumors that 
frequently present at a high clinical stage.  We evaluated 387 tumor foci of 58 separate RCCs 
within conventional, sarcomatoid, and metastatic components. Overall, our study demonstrates 
impressive preservation of chromosomal status across multiple sampled foci within similar 
tumor components as well as comparatively between divergent morphologies and in the 
metastatic setting. While concordance of chromosomal status was preserved in a majority of 
cases, we did identify heterogeneity in a subset. Further study of tumor heterogeneity, 
particularly at the subclonal level, may offer vital information in an age of targeted therapy 
where efficacy remains suboptimal.  
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Figure Legends 
Figure 1. Sampling of tumor foci for fluorescence in situ hybridization (FISH) studies. (A) 
Primary renal cell carcinoma tumors were sampled to identify three separate tumor foci in 
conventional regions and three additional foci in sarcomatoid regions for FISH. Additionally, 
three tumor foci were marked for FISH analysis in each matched metastatic sites including 
lymph node, bone, brain, and lung. 
 
Figure 2. Chromosome 3p status in primary clear cell renal cell carcinoma (including 
conventional and sarcomatoid tumor foci) with matched metastatic sites. (A) Overall 
chromosome 3p status including concordant and discordant chromosome 3p deletions as well as 
clear cell renal carcinoma with no deletion of chromosome 3p. (B-C) Sarcomatoid and 
conventional clear cell renal carcinoma morphologies with concordant (all foci) and discordant 
(1 or 2 of 3 foci) deletions of chromosome 3p. A subset with no deletion of chromosome 3p in 
any focus was identified in both morphologies. (D) Concordant deletion (all tumor foci) of 
chromosome 3p in all matched metastatic sites was identified in 10 of 11 cases.  
 
Figure 3. Primary clear cell renal cell carcinoma (CCRCC), sarcomatoid and conventional 
morphologies. (A-B) Transition between conventional and sarcomatoid morphologies, low 
power (A) and high power (B). (C) CCRCC with sarcomatoid features with loss of chromosome 
3p using interphase fluorescence in situ hybridization (FISH; see inset). (D) Sarcomatoid 
CCRCC with no deletion of chromosome 3p (see inset). (E) Conventional CCRCC with loss of 
chromosome 3p by FISH (see inset). (F) Conventional CCRCC with no deletion of chromosome 
3p (see inset). (G) Histogram of FISH signal distribution of a typical CCRCC. G: Green signal 
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corresponding 3p25; R: Red signal corresponding to CEP3. Vertical axis represents the 
percentage of cells showing the specific signal pattern, The signal pattern was denominated as 
#G#R, which present as number of Green signal (3p25) and number of Red signal (CEP3). 
 
Figure 4. Primary clear cell renal cell carcinoma (CCRCC; conventional and sarcomatoid, 
multiple foci) with matched metastatic sites. (A) CCRCC with sarcomatoid features with 
chromosomal 3p deletion in two of three foci using interphase fluorescence in situ hybridization 
(FISH). (B) Conventional CCRCC with chromosomal 3p deletion in two of three foci by FISH. 
(C) Matched metastatic CCRCC to lung, 7 years status post nephrectomy, with chromosomal 3p 
deletion by FISH. (D) Matched metastatic CCRCC to brain, 11 years status post nephrectomy, 
with chromosomal 3p deletion by FISH. 
 
Figure 5. Chromosome 7 and 17 statuses in papillary renal cell carcinoma (PRCC; including 
conventional and sarcomatoid tumor foci) with matched metastatic sites. (A) Overall, all six 
PRCC carcinoma tumors demonstrated trisomy 7 and 17 in conventional and sarcomatoid tumor 
foci. (B-C) Trisomy 7 and 17 was identified in single tumor focus in both the sarcomatoid and 
conventional sampling demonstrating minor discordance. (D) Matched metastatic PRCC 
demonstrated trisomy 7 and 17 in concordance with the primary lesions.  
 
Figure 6. Primary (conventional and sarcomatoid) and matched metastatic papillary renal cell 
carcinoma (PRCC). (A) Transition between conventional and sarcomatoid PRCC, low power. 
(B) Sarcomatoid PRCC, multiple foci, with trisomy 7 and 17 using interphase fluorescence in 
situ hybridization (FISH; inset). (C) Conventional PRCC, multiple foci, with trisomy 7 and 17 
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using FISH (inset). (D) Matched metastatic PRCC with trisomy 7 and 17 by FISH (inset). (E) 
Histogram of Chromosome 7/17 FISH signal representing a typical PRCC. G: Green signal 
corresponding CEP17; R: Red signal corresponding to CEP7. Vertical axis represents the 
percentage of cells showing the specific signal pattern, which was denominated as #G#R, which 
present as number of Green signal (CEP17) and number of Red signal (CEP7). 
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Table 1. Demographics and Histopathologic Features 
 Age 
(years) 
Male to 
Female 
Ratio 
(M:F) 
Tumor 
Size (mm) 
Sarcomatoid 
Features 
(range, %) 
Pathologic 
Stage (pT) 
at 
Diagnosis  
(when 
available) 
Metastatic 
Samples 
Available for 
Molecular 
Analysis 
Clear Cell 
Renal Cell 
Carcinoma 
(n = 52) 
57 (mean) 
28 – 76 
(range) 
1.3 : 1.0 106 
(mean) 
43 to 205 
(range) 
< 5 to 90% pT1 = 3 
pT2 = 3 
pT3 = 32 
pT4 = 4 
n = 11 (15%) 
bone, brain, 
gastrointestinal, 
liver, lymph 
node, and lung 
Papillary 
Renal Cell 
Carcinoma 
(n = 6) 
54 (mean) 
28 – 77 
(range) 
5.0 : 1.0 71 (mean) 
20 to 150 
(range) 
<5 to 60% pT1 = 1 
pT2 = 2 
pT3 = 3 
 
n = 2 (33%) 
Small bowel 
and lung 
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